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Abstract
Background: Diagnosis of Pneumocystis jirovecii pneumonia (PCP) is challenging, particularly in developing countries. Highly
sensitive diagnostic methods are costly, while less expensive methods often lack sensitivity or specificity. Cost-effectiveness
comparisons of the various diagnostic options have not been presented.
Methods and Findings: We compared cost-effectiveness, as measured by cost per life-years gained and proportion of
patients successfully diagnosed and treated, of 33 PCP diagnostic options, involving combinations of specimen collection
methods [oral washes, induced and expectorated sputum, and bronchoalveolar lavage (BAL)] and laboratory diagnostic
procedures [various staining procedures or polymerase chain reactions (PCR)], or clinical diagnosis with chest x-ray alone.
Our analyses were conducted from the perspective of the government payer among ambulatory, HIV-infected patients with
symptoms of pneumonia presenting to HIV clinics and hospitals in South Africa. Costing data were obtained from the
National Institutes of Communicable Diseases in South Africa. At 50% disease prevalence, diagnostic procedures involving
expectorated sputum with any PCR method, or induced sputum with nested or real-time PCR, were all highly cost-effective,
successfully treating 77–90% of patients at $26–51 per life-year gained. Procedures using BAL specimens were significantly
more expensive without added benefit, successfully treating 68–90% of patients at costs of $189–232 per life-year gained. A
relatively cost-effective diagnostic procedure that did not require PCR was Toluidine Blue O staining of induced sputum ($25
per life-year gained, successfully treating 68% of patients). Diagnosis using chest x-rays alone resulted in successful
treatment of 77% of patients, though cost-effectiveness was reduced ($109 per life-year gained) compared with several
molecular diagnostic options.
Conclusions: For diagnosis of PCP, use of PCR technologies, when combined with less-invasive patient specimens such as
expectorated or induced sputum, represent more cost-effective options than any diagnostic procedure using BAL, or chest
x-ray alone.
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Introduction
Pneumocystis jirovecii causes a fungal pneumonia (PCP) affecting
HIV-infected and other immunocompromised persons worldwide
[1]. Although highly active anti-retroviral therapy (HAART) and
PCP prophylaxis, usually with cotrimoxazole (CTX), have reduced
the burden of PCP among AIDS patients in developed countries
[2,3,4,5], PCP remains an important cause of HIV-related
morbidity and mortality throughout much of the developing
world [1]. The prevalence of PCP among HIV-infected African
children with pneumonia ranges from 10 to 49% [6,7,8,9,10], with
mortality as high as 80% [11]. Among African adults, in whom the
disease is often misdiagnosed as smear-negative TB [12,13,14],
increases in PCP diagnoses have been noted during the past 15
years [15,16,17,18,19,20]. In Southeast Asia, PCP prevalence
among HIV-infected children and adults with pneumonia has
been reported to be as high as 66% [21,22,23]. Among HIV-
uninfected persons, those at risk of PCP include persons receiving
immunosuppressive therapies, such as renal transplant patients
(estimated cumulative PCP incidence: 0.4%) [24,25], patients
undergoing immunosuppressive therapy for connective tissue
disorders [26], and children with chronic lung diseases [27].
Mortality from PCP among HIV-uninfected patients can be as
high as 40% [1].
Laboratory-based diagnosis of PCP is a two-step procedure,
involving specimen collection and pathogen detection (referred to
hereafter as the ‘diagnostic procedure’). Specimens can be
collected from oral washes (OW), expectorated (ES) or induced
(IS) sputum, tracheal secretions, broncho-alveolar lavage (BAL), or
transbronchial biopsies from patients; the latter two require
bronchoscopy. Several different methods can be employed for
pathogen detection on all specimen types, including immunoflu-
orescence microscopy (IFA), Pneumocystis cyst wall stains [Toluidine
Blue O (TBO) and calcofluor white (CW)], Pneumocystis trophozoite
stains [Grocott’s methenamine silver stain (GMS), Diff-Quick
(DQ), and Papanicolaou], or single-round polymerase chain
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PCR (rtPCR) [15,28,29,30] to amplify genomic DNA.
However, accurate diagnosis of PCP poses multiple challenges.
While the procedures to obtain oral washes and sputa are less
invasive than that for BAL, they are also less effective at obtaining
sufficient numbers of organisms for visualization with diagnostic
stains. In contrast, the cost and invasiveness of bronchoscopy and
the technical skill it requires render it unfeasible in many areas of
the world. Pathological interpretations of stained slides are
subjective and nonspecific; sensitivity is dependent on the burden
of pathogen in the sample, the specimen type employed, and the
skill and experience of the technician examining the sample.
Among the pathogen detection methods, the most sensitive is
PCR; however, it may be technologically and economically
impractical for much of the developing world. Because of these
factors, clinicians often use chest x-rays and clinical evaluations as
the sole diagnostic method for Pneumocystis pneumonia. Although
many studies have evaluated the test characteristics of different
diagnostic methods [28,29,30,31,32,33,34,35,36,37,38,39,40,41,
42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,-
63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80], compar-
isons of costs and outcomes have not been presented.
This report reviews available diagnostic procedure options for
PCP, as well as the cost-effectiveness of each option as a function
of procedural cost, sensitivity, and specificity. The outcome
measures of interest are the proportion of PCP patients successfully
treated and the cost per life-year gained. The analysis is considered
from the perspective of the health care payer in developing
countries (typically the government). The results should help guide
decision-making with respect to diagnostic options for PCP in the
developing world.
Methods
Assumptions
Patient population and setting. This analysis is conducted
among ambulatory HIV-infected patients in South Africa.
Test qualities and diagnostic costs. Estimates of sensitivity
and specificity of diagnostic procedures used in the model are
shown in Table 1 and are based on reports from the literature
(chest x-ray alone, oral wash with DQ, PCR, nested PCR, and
rtPCR; expectorated sputum with GMS, TBO, CW; induced
sputum with DQ, GMS, TBO, IS, IFA, PCR, nPCR; BAL with
DQ, GMS, TBO, CW, IFA, PCR, nPCR, rtPCR) [29,30,31,36,
38,39,40,44,47,48,49,50,52,54,55,57,59,60,61,62,63,64,65,66,67,
68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84], or estimated
by the authors (oral wash with IFA, GMS, CW, TBO; expectorated
sputum with DQ, IFA, PCR, nPCR, or rtPCR; induced sputum
with rtPCR). Although all of the above-referenced literature was
consulted, for diagnostic procedures involving any form of PCR,
only studies which targeted the mitochondrial large subunit
ribosomal RNA were used for estimations of sensitivity and
specificity [28,29,36,48,51,54,55,57,63,64,67,68,69,71,72,75,76,78,
85,86]. For tests for which data did not exist in the literature,
estimations of test characteristics were based on interpolation and
pre-existing knowledge of the sensitivity and specificity of other tests
in the same diagnostic category (e.g., we assumed that expectorated
sputum with DQ, for which we did not find published reports,
wouldbeintermediateinsensitivitybetweenoralwashwithDQand
induced sputum with DQ, for which we were able to reference
published reports.)
Estimates of costs include required materials and personnel time
(Tables S1 and S2). Total costs for diagnostic procedures are
included in Table 1. Estimated salaries for laboratory and health
care workers are available in Appendix S1. Except where stated,
all cost and time estimates were provided by the National Institute
of Communicable Diseases in South Africa.
Others. The value referred to as ‘prevalence’ refers
specifically to the prevalence of disease among patients with
signs and symptoms of PCP who would normally warrant testing
at a given hospital or clinic. It does not refer to the population
prevalence of disease. This value will differ regionally; some
hospitals or clinics might test all patients with respiratory disease
and negative AFB smears, while others will test only patients who
have a chest x-ray typical for PCP.
Table 1. Model inputs and costs: Sensitivity and specificity of
diagnostic procedures, based on estimates derived from
existing studies (see text) or, when reference studies not
available, from author estimation.
Diagnostic Specimen collection Sensitivity Specificity Cost (USD)
CXR None 0.86 0.40 $40.00
DQ Oral wash 0.30 1.00 $2.32
Expectorated sputum 0.60 1.00 $2.22
Induced sputum 0.75 1.00 $8.72
Bronchoalveolar lavage 0.75 1.00 $77.12
GMS Oral wash 0.30 1.00 $4.21
Expectorated sputum 0.52 0.95 $4.11
Induced sputum 0.70 0.96 $10.61
Bronchoalveolar lavage 0.82 0.98 $79.01
TBO Oral wash 0.30 1.00 $0.93
Expectorated sputum 0.71 1.00 $0.83
Induced sputum 0.75 1.00 $7.33
Bronchoalveolar lavage 0.80 1.00 $75.73
CW Oral wash 0.30 1.00 $2.94
Expectorated sputum 0.33 1.00 $2.84
Induced sputum 0.57 1.00 $9.34
Bronchoalveolar lavage 0.78 1.00 $77.74
IFA Oral wash 0.30 1.00 $20.79
Expectorated sputum 0.50 1.00 $20.69
Induced sputum 0.81 1.00 $27.19
Bronchoalveolar lavage 1.00 1.00 $95.59
PCR Oral wash 0.71 0.99 $8.78
Expectorated sputum 0.85 0.99 $8.68
Induced sputum 0.94 0.99 $15.18
Bronchoalveolar lavage 1.00 0.94 $83.58
nPCR Oral wash 0.83 1.00 $10.32
Expectorated sputum 0.91 1.00 $10.22
Induced sputum 1.00 1.00 $16.72
Bronchoalveolar lavage 1.00 0.89 $85.12
rtPCR Oral wash 0.89 0.94 $13.84
Expectorated sputum 0.92 0.94 $13.74
Induced sputum 0.95 0.90 $20.24
Bronchoalveolar lavage 0.99 0.80 $88.64
CXR: Chest x-ray; DQ: Diff-Quick; GMS: Grocott’s Methenamine Silver Stain; TBO:
Toluidine Blue O; CW: Calcofluor white stain; IFA: Immunofluorescence; PCR:
Polymerase chain reaction; nPCR: nested PCR; rtPCR: real-time (quantitative)
PCR.
doi:10.1371/journal.pone.0023158.t001
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20%, and 50%. Treatment failure, whether related to insufficient
adherence to treatment or breakthrough infections during
treatment to which the patient is adherent, is assumed to occur
among 10% of patients (Table S3).
Treatment costs are based on a single, 21-day regimen with oral
CTX (Table S3). Patients are assumed to not be taking CTX at
the time of diagnosis.
Life-years gained. In studies carried out before the year
2000, median survival time after AIDS diagnosis among patients
in developing countries not on antiretroviral therapy was
calculated to be approximately one year [87]. In the absence of
treatment, PCP is generally accepted to lead to rapid death.
Therefore, we assumed that diagnosis and appropriate treatment
led to a single life-year gained among patients with PCP,
compared with patients who were not diagnosed correctly.
Model flow. An example of model flow with sample values is
depicted in Figure 1. ‘Ill patients’ refers to patients with PCP; ‘well
persons’ refers to persons without PCP (although persons in this
group likely have another illness, since they are undergoing testing).
At a given PCP prevalence among persons tested, the number of ill
patients correctly diagnosed is calculated as the sensitivity of the
diagnostic procedure (Table 1) multiplied by the total number of ill
patients. The number of well persons incorrectly classified as ill is
equal to the total number of well persons, minus the procedural
specificity (Table 1) multiplied by the total number of well persons.
The total number of persons classified as ill is the sum of these values.
Total diagnostic procedural costs are calculated as a sum of the health
care worker and laboratory staff costs and material costs for the
specimen collection and the diagnostic test procedures (Table 1 and
Tables S1 and S2).
All persons diagnosed as PCP-positive (correctly or incorrectly)
are assumed to receive a full course of treatment. Treatment
failure rates are considered as a combination of failure-to-adhere
and breakthrough infection rates (Table S3). The number of
patients who fail treatment is equal to the number of ill patients
correctly classified as ill who undergo treatment, multiplied by the
treatment failure rate. Because each patient is assumed to gain a
single year of life from correct treatment, total life-years gained is
equal to the number of ill patients correctly diagnosed minus those
for whom treatment did not successfully treat infection (Figure 1).
The proportion of ill patients successfully treated is represented
by the number of patients successfully treated divided by the
number ill, while the proportion unnecessarily treated is equal to
the number of well persons treated divided by the total number of
well persons. Total treatment costs are equal to the total number
of well persons and ill patients who receive treatment, multiplied
by the estimated treatment cost. Finally, the total diagnostic and
treatment cost per life-year gained (the cost-effectiveness ratio) is
equal to the sum of the total diagnostic costs and the total
treatment costs, divided by the number of ill patients successfully
treated. The incremental cost-effectiveness ratios of the most
effective options were then calculated.
Relapse rates are not considered. Start-up and indirect costs
(building costs, laboratory equipment purchase, electricity, train-
ing) are also not considered, as they will differ greatly by region
and available pre-existing infrastructure.
Sensitivity analyses. Sensitivity analyses were performed by
varying specific parameters, including treatment costs, treatment
failure rates, and costs of diagnostic procedures, over a range of
plausible values to determine the impact of uncertainty in the data,
and the robustness of results.
Figure 1. Model flow. ‘Ill patients’ refers to patients with PCP. ‘Well persons’ refers to persons without PCP, regardless of their health status
otherwise. Patients successfully treated are assumed to gain one life-year.
doi:10.1371/journal.pone.0023158.g001
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Results from the analyses are presented in Table 2. Nearly all
laboratory-based diagnostic procedures have an estimated specificity
.90%; thus, few false positives occur even when employing the least
sensitive diagnostic procedures (Table 1) and specificity does not
contribute to the cost-effectiveness of most diagnostic procedures (the
exception is chest x-ray). In general, diagnostic procedures that resulted
in the highest proportion of patients successfully treated involved PCR,
nPCR, or rtPCR, regardless of the specimen type used for diagnosis.
Only one non-PCR-based laboratory diagnostic procedure (IFA with
BAL) resulted in successful treatment of $75% of patients, while all
PCR-based diagnostic procedures except one (PCR with OW) resulted
in successful treatment of $75% of patients (Table 2).
At a disease prevalence of 50%, eight diagnostic procedures had
average cost-effectiveness ratios #$25 per life-year gained; among
these, the most effective (in terms of proportion of PCP patients
successfully treated) were IS/TBO, ES/TBO, and ES/DQ
(successfully treating 68%, 64%, and 54% of PCP patients,
respectively, at $25, $6, and $11 per life-year gained, respectively).
Fifteen procedures had an average cost-effectiveness ratio of $26–
$100 per life-year gained; among these, the most effective
procedures were IS/nPCR, IS/rtPCR, and IS/PCR (resulting in
successful treatment of 90%, 86%, and 85% of PCP patients,
respectively, at $40, $51, and $39 per life-year gained). Above $100
per life-year gained, the most effective procedures were BAL/
nPCR, BAL/IFA, and BAL/PCR, all successfully treating 90% of
patients and costing $193, $216, and $189 per life-year gained,
Table 2. Model outputs: Average Cost effectiveness ratio (ACER) (total diagnostic and treatment cost per life-year gained) for each
diagnostic procedure.
Diagnostic Specimen
% of patients
successfully treated
ACER (5%
prevalence)
ACER (20%
prevalence)
ACER (50%
prevalence)
CXR None 77.0% $1,077 $270 $109
DQ Oral wash 27.0% $175 $46 $20
Expectorated sputum 54.0% $85 $24 $11
Induced sputum 67.5% $261 $68 $29
Bronchoalveolar lavage 67.5% $2,288 $574 $232
GMS Oral wash 27.0% $315 $81 $34
Expectorated sputum 46.8% $184 $48 $21
Induced sputum 63.0% $343 $88 $37
Bronchoalveolar lavage 73.8% $2,146 $539 $217
TBO Oral wash 27.0% $72 $20 $10
Expectorated sputum 64.3% $29 $10 $6
Induced sputum 67.5% $220 $57 $25
Bronchoalveolar lavage 72.0% $2,107 $529 $213
CW Oral wash 27.0% $221 $58 $25
Expectorated sputum 29.7% $194 $51 $22
Induced sputum 51.3% $367 $94 $39
Bronchoalveolar lavage 70.2% $2,218 $557 $225
IFA Oral wash 27.0% $1,543 $388 $157
Expectorated sputum 45.0% $923 $233 $95
Induced sputum 72.9% $749 $190 $78
Bronchoalveolar lavage 90.0% $2,127 $534 $216
PCR Oral wash 63.9% $279 $72 $31
Expectorated sputum 76.5% $231 $60 $26
Induced sputum 84.6% $363 $93 $39
Bronchoalveolar lavage 90.0% $1,864 $468 $189
nPCR Oral wash 74.7% $279 $72 $31
Expectorated sputum 81.9% $253 $65 $28
Induced sputum 90.0% $375 $96 $40
Bronchoalveolar lavage 90.0% $1,901 $477 $193
rtPCR Oral wash 80.1% $353 $90 $38
Expectorated sputum 82.8% $339 $87 $36
Induced sputum 85.5% $483 $123 $51
Bronchoalveolar lavage 89.1% $2,005 $503 $203
CXR: Chest x-ray; DQ: Diff-Quick; GMS: Grocott’s Methenamine Silver Stain; TBO: Toluidine Blue O; CW: Calcofluor white stain; IFA: Immunofluorescence; PCR: Polymerase
chain reaction; nPCR: nested PCR; rtPCR: real-time (quantitative) PCR.
doi:10.1371/journal.pone.0023158.t002
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average cost-effectiveness ratio of $109 per life-year gained and the
successful treatment of 77% of patients. Although total costs varied
with disease prevalence, relative costs and cost-effectiveness ratios
did not (Table 2).
The scatterplot in Figure 2 demonstrates the relationship
between cost and outcomes of the individual diagnostic proce-
dures. The best outcomes (the highest proportion of patients
successfully treated as a result of proper diagnosis and subsequent
treatment) are achieved using procedures on the right-hand side of
the plot, while the least expensive procedures (per life-year gained)
are on the bottom of the plot. The most cost-effective procedures,
then, are those that cluster in the bottom right. These procedures
include any combination of induced sputum with PCR, nPCR, or
rtPCR; expectorated sputum with nPCR or rtPCR; and oral wash
with rtPCR, all resulting in the successful treatment of 80–90% of
PCP patients at relatively reduced costs per life-year gained
(Figure 2). The most expensive procedures per life-year gained,
represented as squares in the top right of the figure, all involve
BAL, and result in 68–90% of patients being successfully treated.
It is worth noting that the diagnostic procedure with the highest
cost per life-year gained (DQ/BAL, at $232 per life-year gained)
results in similar proportions of patients successfully treated (68%)
to the diagnostic procedure with the lowest cost per life-year
gained (ES/TBO, successfully treating 64% of PCP patients at $6
per life-year gained).
Incremental cost-effectiveness of selected options
We evaluated incremental cost-effectiveness among diagnostic
options which resulted in successful treatment of at least 2/3 (67%)
Figure 2. Scatterplot showing total costs for diagnostic procedures and treatment, per life-year gained, at 50% prevalence among
population tested. Triangles represent procedures involving oral washes; circles represent procedures involving expectorated sputum; lines
represent procedures involving induced sputum; and squares represent procedures involving BAL. All white data points outlined in black indicate
procedures using the Diff-Quick test (1–4); red indicates procedures using GMS (5–8); orange indicates procedures using TBO (9–12); light green
indicates procedures using calcofluor white (13–16); dark green indicates procedures using IFA (17–20); black indicates procedures using PCR (21–24);
purple indicates procedures using nPCR (25–28); and blue indicates procedures using rtPCR (29–32). Figure 2 Legend: 1: DQ/OW; 2: DQ/ES; 3: DQ/IS; 4:
DQ/BAL; 5: GMS/OW; 6: GMS/ES; 7: GMS/IS; 8: GMS/BAL; 9: TBO/OW; 10: TBO/ES; 11: TBO/IS; 12: TBO/BAL; 13: CW/OW; 14: CW/ES; 15: CW/IS; 16: CW/
BAL; 17: IFA/OW; 18: IFA/ES; 19: IFA/IS; 20: IFA/BAL; 21: PCR/OW; 22: PCR/ES; 23: PCR/IS; 24: PCR/BAL; 25: nPCR/OW; 26: nPCR/ES; 27: nPCR/IS; 28: nPCR/
BAL; 29: rtPCR/OW; 30: rtPCR/ES; 31: rtPCR/IS; 32: rtPCR/BAL; CXR: chest x-ray.
doi:10.1371/journal.pone.0023158.g002
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effective and more expensive) and weakly dominated (equally
effective but more expensive, or equal in cost but less effective)
options, five procedures remained for inclusion in an incremental
cost-effectiveness analysis: induced sputum with TBO, PCR, or
nPCR; and expectorated sputum with nPCR or rtPCR (Table 3).
Using nPCR with expectorated or induced sputum provided a
relatively higher benefit at lower cost ($43 and $60 for each
additional life-year gained, respectively), compared with the next-
least-effective procedure (Table 3).
Sensitivity analysis
Variations in the cost of the diagnostic procedure had the most
impact on cost per life-year gained in sensitivity analyses.
Reducing the cost of the diagnostic procedures by 50% led to
an approximate 50% reduction in cost per life-year gained, while
doubling it led to approximately a two-fold increase in cost per life-
year gained (Table S4). Modifying other factors, including the
procedural sensitivity, specificity, treatment failure rates, or
treatment cost had little effect on the overall cost per life-year
gained. None of the analyses examined affected the relative cost-
effectiveness of the diagnostic procedures with respect to each
other.
Discussion
Cost-effectiveness analysis
Three metrics are relevant in this analysis for decision-making
and policy concerning diagnostic testing for PCP: (a) proportion of
PCP patients successfully treated, (b) proportion of well persons
unnecessarily treated, and (c) the total diagnostic and treatment
cost per life-year gained. An ideal test will maximize the first
metric and minimize the second, at the smallest – and most
feasible, for the implementing clinic or geographic region under
consideration – value of the third. Because all laboratory-based
diagnostic procedures considered in this analysis were highly
specific, the effect of (b) is negligible for this analysis; thus, we
presented the results as a function of (a) and (c).
Our results indicate that PCR methodologies are so sensitive
that, specimen type notwithstanding, they represent the most cost-
effective diagnostic options for PCP. When PCR methodologies
are available, they mitigate the need for obtaining highly invasive
specimens, such as BAL, which increase procedural sensitivity at
substantial increases in cost. However, if both PCR and machinery
for sputum induction are unavailable at a given site, the next-best
option could be ES/TBO, which is relatively inexpensive and
simple in terms of specimen collection and laboratory require-
ments for diagnosis. Although the use of chest x-ray alone for
diagnosis can lead to the successful detection and treatment of high
proportions of patients, the cost per life-year gained exceeds that of
other equally-sensitive or more sensitive methods for diagnosing
disease.
In general, the decision about which test is most useful in a
given region will depend on the estimated prevalence of PCP
among persons tested, local technical capacity, and available
financial resources. Individual patient characteristics may affect
decision-making, too; in an already-intubated patient, a BAL will
be meaningfully cheaper than it would be among non-intubated
patients, making the increased sensitivity in specimen collection
more economical as well as practical (as an intubated patient or an
infant will be unable to produce sputum). In addition, BAL might
facilitate the detection of other respiratory pathogens besides
Pneumocystis, such as TB or staphylococcus. Similarly, chest x-rays
can provide information beyond the ability to evaluate a patient
for signs consistent with PCP. However, for the diagnosis of PCP,
providing a patient can produce sputum, the model presented
suggests that there is little added value in carrying out a BAL over
an induced sputum procedure.
There are several limitations to this analysis. First, data were not
available on the sensitivity and specificity of all diagnostic
procedures, creating a need to estimate some values. Even for
procedures for which data were available, the degree of experience
of an administering clinician or laboratory technician could affect
the test’s sensitivity or specificity. Second, indirect costs are not
included in the model. The buildings, equipment, and technical
know-how needed to carry out more advanced molecular
diagnostics such as PCR are not currently in place in all countries.
Where this capacity does exist, it may be unevenly distributed
geographically and might not be accompanied by appropriate
quality assurance measures. Start-up costs to implement these
technologies could be prohibitive for some low-income countries,
and in these areas comparisons of the cost-effectiveness of the
various staining methods might be more useful than considerations
about which PCR methodology is optimal. Finally, we did not
account for differing diagnostic or treatment costs in different
countries or among different patient groups, which could affect
overall cost or cost-effectiveness of different diagnostic options.
However, it is worth noting that, although the costs of all
procedures might differ by country, the relative cost of procedures
is unlikely to differ greatly.
Other considerations
Existing international guidelines call for CTX prophylaxis of
PCP in patients whose CD4+ T cell counts drop below 350 cells/
mm [3]. CTX is also considered the treatment of choice for PCP.
Because diagnostics are not available throughout much of the
Table 3. Incremental cost-effectiveness of a subset of diagnostic procedures for Pneumocystis pneumonia, assuming 50% disease
prevalence.
Specimen collection and
diagnostic procedure
% of patients successfully
treated
Average cost per
life-year gained
Cost per additional life-year gained, compared
with next-least-effective procedure
IS/TBO 0.68 $25 $N/A
ES/nPCR 0.82 $28 $43
ES/rtPCR 0.83 $36 $804
IS/PCR 0.85 $39 $156
IS/nPCR 0.90 $40 $60
IS: Induced sputum; ES: expectorated sputum; TBO: Toluidine Blue O; PCR: polymerase chain reaction; nPCR: nested PCR; rtPCR: real-time (quantitative) PCR.
doi:10.1371/journal.pone.0023158.t003
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can be effective in the treatment of other respiratory pathogens in
addition to PCP [88,89], clinicians in developing countries
frequently diagnose symptomatic patients empirically for PCP.
While this method may capture a high proportion of patients with
disease, it is highly nonspecific and thus may result in many
patients without PCP being treated for the disease. Why should we
consider this important? First, CTX has known toxic side effects:
HIV-infected patients in particular are at risk of adverse reactions
to CTX, including cutaneous reactions [90], fever, neutropenia,
thrombocytopenia, transaminase elevation [91], meningitis [92]
and anaphylaxis [93]. Second, non-judicious use of antimicrobials
has long been recognized as a precursor to increased drug-
resistance for a broad spectrum of pathogens. While reports of
Pneumocystis resistance to CTX are infrequent, some do exist, and
concern about resistance is increasing [94,95,96]. Perhaps as
importantly, treatment for other pathogens, including S. pneumo-
niae, malaria, Salmonella spp, Staphylococcus aureus, and Escherichia coli,
involve the use of CTX, and for these pathogens reports of CTX
drug-resistance are common [97,98,99,100,101,102,103].
The cost-effectiveness of diagnostic testing improves in areas of
higher disease prevalence; testing might become prohibitively
expensive in areas with very low prevalence of disease. However, a
diagnostic protocol that might seem financially unfeasible for
certain regions might be more feasible than suspected if the
prevalence of disease can be increased among the patients selected
for testing. One way to optimize test utility is to use a clinical
algorithm that improves the pre-test probability without incurring
substantial numbers of false negatives. Although no such algorithm
has been formally defined for PCP, clinical differences do exist
between HIV-infected patients with PCP compared with other
pneumonias; PCP patients have a more subacute onset of disease,
ground glass infiltrates on CXR [104], lower oxygen saturation,
lower CD4 cell counts, greater weight loss, more cyanosis, more
severe dyspnea, and higher respiratory rates than non-PCP
patients [15,105]. Utilizing one or a combination of these metrics
might be useful for increasing the prevalence of PCP among the
population to be tested (e.g., increasing the pre-test probability),
provided it did not miss substantial numbers of patients with PCP.
For any disease, when the cost of diagnosis exceeds the cost of
treatment (such as with PCP), the cost-effectiveness of empiric
diagnosis and treatment is directly proportional to the gap between
the diagnostic and treatment costs; thus, when treatment costs are
very low, it’s nearly always more cost-effective to diagnose and
treat patients empirically. In addition, because international
guidelines call for at-risk patients to be on ART and CTX
prophylaxis, the occurrence of PCP in a patient likely represents a
failure of the local health system to provide sufficient opportunities
for HIV patient care and treatment, an inability by the treating
clinic to meet these standards, an inability by the patient to adhere
to the recommended treatment regimen, or drug failure. Thus,
one could argue that efforts should be focused on improving access
to care for HIV patients or adherence to the standards laid out in
international guidelines with respect to ART and CTX treatment,
rather than on diagnosing the precise etiology of infections that
could otherwise have been prevented. This is a valid argument and
such efforts should be supported. However, given the suboptimal
conditions that currently exist with respect to meeting these
guidelines, there are benefits to accurate diagnosis, including
improvements in the understanding of the true prevalence of
disease, which is worthwhile for the purposes of prevention,
control, and allocation of resources. This analysis is not intended
to discourage PCP prophylaxis or diagnosis and treatment among
symptomatic patients in the absence of a laboratory-based
diagnosis, but rather to provide a basis for decisions on diagnostics
for PCP, should an institution desire to implement diagnostic
procedures. For these institutions, particularly in situations of high
disease prevalence, we demonstrate that the elevated sensitivity
and specificity of diagnosis enabled by the use of PCR technologies
could justify the additional costs of obtaining and using them. A
rough calculation demonstrates the power of replacing micro-
scope-based technologies with PCR technologies for the diagnosis
of PCP: in South Africa, the adult HIV infection rate is reported at
20%, with an estimated half a million new infections [106] and
approximately 250,000 persons starting ART each year [107].
Assuming a PCP prevalence of ,20% among HIV-infected
persons starting ART (PCP prevalence among HIV-infected
children is reported to be as high as 52% in South Africa
[7,8,18]), approximately 50,000 persons would start ART with
PCP. Using PCR technologies with expectorated sputum could
result in the successful treatment of between 8,350 and 27,650
more PCP infections (i.e., result in 8,350–27,650 more life-years
gained) than diagnosis with non-molecular-based technologies (or
empiric diagnosis and treatment).
Diagnostic procedural decisions cannot, in practice, be
simplified to numbers alone. Assuming clinicians were aware of
the diagnostic qualities of each test, they could make decisions
outside of the framework presented here, such as conducting
sequential tests (for example, a highly sensitive test followed by a
highly specific test) for diagnostic purposes. In addition, we realize
that most clinicians do not have an array of diagnostic options at
hand, and if a diagnostic protocol is to be implemented, it will be
done at a clinic, hospital, or regional level. However, examples of
molecular diagnostic technologies in resource-limited settings are
increasingly reported, for example with tuberculosis diagnosis
[108,109,110,111]. The fixed costs associated with building
structures and capacity to carry out these technologies will
decrease in proportion to their utility as these technologies
become cheaper and address to increasing arrays of pathogens.
As more patients develop PCP and concerns about CTX drug
resistance grow, it is worth considering whether changes in existing
diagnostic paradigms are warranted for PCP. Choosing subopti-
mal diagnostic methodologies – or no laboratory-based method-
ologies at all, for empirically-diagnosed disease - for a treatable
infection may no longer be justifiable, particularly in high-
prevalence areas. In recognition of the enormous increases in
diagnostic sensitivity available with more technologically complex
procedures such as PCR, we would encourage policymakers,
particularly those in regions where disease prevalence is high
among the population tested, to consider prioritizing the
development of the skills and infrastructure necessary to support
improved diagnostic methods. It is our hope that this analysis can
serve as a guide to help clinicians or policymakers make decisions
about the best use of limited resources.
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